Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) EBIT (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBIT for 5 consecutive years, with -$4.5 million as the latest value for Q4 2020.

  • Quarterly EBIT fell 187.28% to -$4.5 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was -$46.3 million through Dec 2020, down 134.36% year-over-year, with the annual reading at -$14.4 million for FY2025, 60.79% up from the prior year.
  • EBIT for Q4 2020 was -$4.5 million at Forte Biosciences, up from -$5.0 million in the prior quarter.
  • The five-year high for EBIT was $1.4 million in Q3 2018, with the low at -$34.8 million in Q2 2020.
  • Average EBIT over 5 years is -$9.1 million, with a median of -$8.3 million recorded in 2016.
  • The sharpest move saw EBIT soared 114.66% in 2018, then plummeted 5425.28% in 2020.
  • Over 5 years, EBIT stood at -$8.0 million in 2016, then crashed by 34.04% to -$10.7 million in 2017, then crashed by 78.8% to -$19.1 million in 2018, then skyrocketed by 91.81% to -$1.6 million in 2019, then tumbled by 187.28% to -$4.5 million in 2020.
  • According to Business Quant data, EBIT over the past three periods came in at -$4.5 million, -$5.0 million, and -$34.8 million for Q4 2020, Q3 2020, and Q2 2020 respectively.